Recent worldwide terrorist attacks and hoaxes have heightened awareness that more incidents involving weapons of mass destruction (WMD) may occur in the United States. With federal funding assistance, local domestic preparedness programs have been initiated to train and equip emergency services and emergency department personnel in the management of large numbers of casualties exposed to nuclear, biological, or chemical (NBC) agents. Hospital pharmacies will be required to provide antidotes, antibiotics, antitoxins, and other pharmaceuticals in large amounts and/or have the capability for prompt procurement. Pharmacists should become knowledgeable in drug therapy of NBC threats with respect to nerve agents, cyanide, pulmonary irritants, radio-nucleotides, anthrax, botulism, and other possible WMD.
1. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411.
2.
2. Danzig R, Berkoswky PB. Why should we be concerned about biological warfare?JAMA. 1997;278:431-432.
3.
3. Sharp TW, Brennan RJ, Keim M, et al. Medical preparedness for a terrorist incident involving chemical or biological agents during the 1996 Atlanta Olympic games. Ann Emerg Med. 1998;32:214-223.
4.
4. Tucker JB. National health and medical services response to incidents of chemical and biological terrorism. JAMA. 1997;278:362-368.
5.
5. Anteau CM, Williams LA. The Oklahoma bombing: Lessons learned. Crit Care Nurs Clin North Am. 1997;9:231-236.
6.
6. Richards CF, Burstein JL, Waeckerle JF, et al. Emergency physicians and biological terrorism. Ann Emerg Med. 1999;34:183-190.
7.
7. Pesik N, Keim M, Sampson TR. Do U.S. emergency medicine residency programs provide adequate training for bioterrorism?Ann Emerg Med. 1999;34:173-176.
8.
8. Forrow L, Sidel VW. Medicine and nuclear war: from Hiroshima to mutual assured destruction to abolition 2000. JAMA. 1998;280:456-461.
9.
9. Zilinskas RA. Iraq’s biological weapons: the past as future?JAMA. 1997;278:418-424.
10.
10. Lebeda FJ. Deterrence of biological and chemical warfare: a review of policy options. Mil Med. 1997;162:156-161.
11.
11. Dart RC, Stark Y, Fulton B, et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. JAMA. 1996;276:1508-1510.
12.
12. Woolf AD, Chrisanthus K. On-site availability of selected antidotes: results of a survey of Massachusetts hospitals. Am J Emerg Med. 1997;15:62-66.
13.
13. Chyka PA, Conner HG. Availability of antidotes in rural and urban hospitals in Tennessee. Am J Hosp Pharm. 1994;51:1346-1348.
14.
14. Santucci KA, Shah BR, Linakis JG. Acute isoniazid exposures and antidote availability. Pediatr Emerg Care. 1999;15:99-101.
15.
15. Antidotes dangerously understocked in Colorado, Montana, and Nevada. Am J Health Syst Pharm. 1997;54:16, 19.
16.
16. Webster KS, Burda AM, Sigg T, et al. Antidote preparedness of Illinois hospitals. Pharmacotherapy. 1999;19:1229-1230.
17.
17. Preparedness and Response for Terrorist Incidents Amendment (Nunn-Lugar-Domenici Act) of 1996. Public Law Number G250-12, Federal Emergency Management Agency; 1996:1-24.
18.
18. The Centers for Disease Control and Prevention. Strategic national stockpile; December 2002. Available at: http://www.bt.cdc.gov/stockpile.
19.
19. US Department of Justice Office of Justice Programs. April 2003. Available at: http://ojp.usdoj.gov/terrorism/conferences.htm.
20.
20. US Army Medical Research Institute of Infectious Diseases. USAMRIID’s Medical Management of Chemical Casualties Handbook. 4th ed.Fort Detrick, Md: Chemical Casualty Care Division, USAMRIID; 2000.
21.
21. 2004 Drug Topics® Red Book. 108th ed.Montvale, NJ: Medical Economics Company, Inc; 2003.
22.
22. AHFS Drug Information 2003. Bethesda, Md: American Society of Health-System Pharmacists; 2003.
23.
23. Schier JG, Mehta R, Mercurio-Zappala M, Nelson LS, Howland MA, Hoffman RS. Preparing for chemical terrorism: stability of expired atropine. J Toxicol Clin Toxicol. 2002;40:625-626.
24.
24. Kozak RJ, Siegel S, Kuzma J. Rapid atropine synthesis for the treatment of massive nerve agent exposure. Ann Emerg Med. 2003;41:685-688.
25.
25. Geller RJ, Lopez GP, Cutler S, Lin D, Bachman GF, Gorman SE. Atropine availability as an antidote for nerve agent casualties: validated rapid reformulation of high-concentration atropine from bulk powder. Ann Emerg Med. 2003;41:453-456.
26.
26. Dix J, Freeman B, Hess M, et al. Atropine stability for use in mass chemical terrorism events. J Toxicol Clin Toxicol. 2002;40:696.
27.
27. Field Manual: Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Departments of the Army, the Navy, and the Air Force, and Commandant, Marine Corps. Available at: http://nbc-med.org/SiteContent/MedRef/OnlineRef/FieldManuals/fm8_285/toc.htm.
28.
28. Diomed® Pharmaceutical Company. May 2003. http://www.diomed.com.tr/default.asp.
29.
29. Douidar SM. Nebulized sodium bicarbonate in acute chlorine inhalation. Pediatr Emerg Care. 1997;13:406-407.
30.
30. Bosse GM. Nebulized sodium bicarbonate in the treatment of chlorine gas inhalation. J Toxicol Clin Toxicol. 1994;32:233-241.
31.
31. Vinsel PJ. Treatment of acute chlorine gas inhalation with nebulized sodium bicarbonate. J Emerg Med. 1990;8:327-329.
32.
32. Delgado J, Hurlbut KM, Bogdan GM, et al. Poisindex®, Arsenic[monograph on CD-ROM]. Vol 116. Englewood, Colo: Micromedex® Healthcare Series; 2002.
33.
33. Aposhian HV, Carter DE, Hoover TD, et al. DMSA, DMPS, and DMPA as arsenic antidotes. Fundam Appl Toxicol. 1984;2(2 pt 2):S58-S70.
34.
34. Aposhian HV, Mershon MM, Brinkley FB, et al. Anti-lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid. Life Sci. 1982;31:2149-2156.
36. Inns RH, Rice P. Efficacy of dimercapto chelating agents for the treatment of poisoning by percutaneously applied dichloro (2-chlorovinyl) arsine in rabbits. Hum Exp Toxicol. 1993;12:241-246.
37.
37. Inns RH, Rice P, Bright JE, et al. Evaluation of the efficacy of dimercapto chelating agents for the treatment of systemic arsenic poisoning in rabbits. Hum Exp Toxicol. 1990;9:215-220.
38.
38. Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, et al. Arsenate reductase II: purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem Res Toxicol. 2002;15:692-698.
39.
39. Coppock R, Hurlbut KM. Poisindex®, MustardGas [monograph on CD-ROM]. Vol 116. Englewood, Colo: Micromedex®Healthcare Series; 2001.
40.
40. Chemical weapons: shifting the goal posts [editorial]. Lancet Neurol. 2002;1:254-255.
41.
41. Hendee W, Palmer R, Hall AH, et al. Poisindex®, Radiation[monograph on CD-ROM]. Vol 116. Englewood, Colo: Micromedex® Healthcare Series; 2001.
42.
42. Lincoln TA. Importance of initial management of persons internally contaminated with radionuclides. Am Ind Hyg Assoc J. 1976;37:16-21.
43.
43. Ricks RC, Lowry PC, Townsend RD. Radiogardase-Cs insoluble Prussian Blue (ferric hexacyanoferrate, Fe4[Fe(CN)6]3). Oak Ridge, Tenn: Radiation Emergency Assistance Center/Training Site; November 2002.
46. Physicians’ Desk Reference. 57th ed.Montvale, NJ: Medical Economics Company; 2003:32-43.
47.
47. CDER KI Taskforce. Guidance potassium iodide as a thyroid blocking agent in radiation emergencies. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. 2001. Available at: http://www.fda.gov/cder/guidance/index.htm.
48.
48. CDER KI Taskforce. Home preparation procedure for emergency administration of potassium iodide tablets to infants and small children. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. 2002. Available at: http://fda.gov/cder/drugprepare/kiprep.htm.
49.
49. US Army Medical Research Institute of Infectious Diseases. USAMRIID’s Medical Management of Biological Casualties Handbook. 4th ed.Fort Detrick, Md: Operational Medicine Department, USAMRIID; 2001. Available at: http://www.usamriid.army.mil/education/bluebook.html.
50.
50. Inglesby TB, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999;281:1735-1745.
51.
51. Hurlbut KM. Poisindex®, Anthrax [monograph on CD-ROM]. Vol 116. Englewood, Colo: Micromedex® Healthcare Series; 2002.
52.
52. Centers for Disease Control and Prevention. Update on cholera vaccine, August 2000. Available at: http://cdc.gov/travel/other/cholera-vaccine.htm.
53.
53. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999;281:2127-2137.
54.
54. Weltzin R, Liu J, Pugachev KV, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003;9:1125-1130. Available at: http://www.acambis.com/default.asp?id=591.
55.
55. Centers for Disease Control and Prevention. Guide B: vaccination guidelines for state & local health agencies. November 2002. Available at: http://www.bt.cdc.gov/agent/smallpox/responseplan/index.asp.
56.
56. Hogan CJ, Harchelroad F. Smallpox. Emedicine. March 2003. Available at: http://www.emedicine.com/emerg/topic885.htm.
57.
57. Thorne CD, Hirshon JM, Himes CD, McDiarmid MA. Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guidelines and policies and procedures. Ann Emerg Med. 2003;42:665-680.
58.
58. Centers for Disease Control and Prevention. Smallpox fact sheet: medical management of smallpox (vaccinia) vaccine adverse reactions—vaccina immune globlulin and cidofovir. February 2003. Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp.
